Results 161 to 170 of about 76,992 (320)

Rational Choice of Amide‐Based Electrolytes Toward High‐Power Rechargeable Lithium‐Air Batteries

open access: yesEnergy Technology, EarlyView.
The cycle performance of lithium‐air batteries with amide‐based electrolytes is studied in a stack‐type open‐cell system. The gravimetric analysis demonstrates continuous weight loss by electrolyte evaporation, along with weight increase/decrease by oxygen reduction/evolution reactions, revealing superior cyclability under high‐rate cycle conditions ...
Akihiro Nomura   +3 more
wiley   +1 more source

What a State: Why the U.S. is Still Bad for Your Health (Policy)

open access: yesThe International Journal of Health Planning and Management, EarlyView.
ABSTRACT The second Trump administration's centrepiece legislation, the modestly‐named Big Beautiful Bill, passed by the House of Representatives and going through the Senate at time of writing, offers an opportunity to reflect upon how the U.S. state affects health policy and the prospects for equitable access to affordable healthcare.
Calum Paton
wiley   +1 more source

Cycles in hamiltonian graphs of prescribed maximum degree

open access: bronze, 2003
Antoni Marczyk, Mariusz Woźniak
openalex   +1 more source

Selenide‐driven electron delocalization in Co single‐atom@metal‐cluster sites on periodic macroporous carbon framework for synergistic oxygen/iodine electrocatalysis in zinc‐air/iodine hybrid batteries

open access: yesInfoMat, EarlyView.
Zinc‐air/iodine hybrid batteries (ZAIHBs) hold great promise for energy storage but require advanced bifunctional catalysts to overcome sluggish oxygen and iodine redox kinetics. This study develops a hierarchical 3DOM Co(Se)/NC catalyst with single Co atoms and Co/CoSe2 nanoclusters that optimize redox energetics and mass transport.
Xueli Ji   +7 more
wiley   +1 more source

Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma

open access: yesThe Journal of Clinical Pharmacology, EarlyView.
Abstract Valemetostat is a dual inhibitor of EZH2/1 approved in Japan for the treatment of relapsed/refractory (R/R) adult T–cell lymphoma/leukemia (ATLL) and R/R peripheral T–cell lymphoma (PTCL). It is administered orally once daily (QD) at 200 mg. Here, we present comprehensive population pharmacokinetic (PPK) and exposure–response (ER) analyses of ...
Hiroyuki Inoue   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy